Nebulised interferon beta-1a for patients with COVID-19

Type 1 interferons as a potential treatment against COVID-19

(2020) Erwan Sallard et al.   ANTIVIRAL RESEARCH

Persistent Symptoms in Patients After Acute COVID-19

(2020) Angelo Carfì et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

(2020) Jérôme Hadjadj et al.   SCIENCE

Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

(2020) Yaseen M. Arabi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

(2020) Paul Bastard et al.   SCIENCE

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Phillip D Monk et al.   Lancet Respiratory Medicine

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

(2019) Rudragouda Channappanavar et al.   JOURNAL OF CLINICAL INVESTIGATION

Type I Interferons as Regulators of Lung Inflammation

(2017) Spyridon Makris et al.   Frontiers in Immunology

Interferon induction and function at the mucosal surface

(2013) Russell K. Durbin et al.   IMMUNOLOGICAL REVIEWS